CG Oncology (NASDAQ:CGON) Price Target Raised to $80.00

CG Oncology (NASDAQ:CGON) had its price target lifted by Wedbush from $77.00 to $80.00 in a research note published on Monday, MarketBeat.com reports. The brokerage currently has an outperform rating on the stock.

A number of other equities research analysts have also recently commented on CGON. Piper Sandler raised their target price on shares of CG Oncology from $55.00 to $70.00 and gave the stock an “overweight” rating in a research note on Friday, January 16th. Wall Street Zen cut shares of CG Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. JPMorgan Chase & Co. raised their target price on shares of CG Oncology from $65.00 to $91.00 and gave the stock an “overweight” rating in a research note on Friday, April 17th. Royal Bank Of Canada raised their target price on shares of CG Oncology from $73.00 to $79.00 and gave the stock an “outperform” rating in a research note on Monday, April 27th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of CG Oncology in a research note on Monday, April 20th. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $81.27.

CG Oncology Stock Up 2.7%

Shares of NASDAQ CGON opened at $74.00 on Monday. The firm’s 50-day moving average price is $66.77 and its 200-day moving average price is $53.68. The company has a market cap of $6.53 billion, a PE ratio of -31.76 and a beta of 0.41. CG Oncology has a 52-week low of $23.32 and a 52-week high of $74.35.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.13). The firm had revenue of $1.08 million for the quarter, compared to analysts’ expectations of $0.45 million. As a group, equities research analysts anticipate that CG Oncology will post -2.77 EPS for the current fiscal year.

Insider Buying and Selling at CG Oncology

In other CG Oncology news, Director James Mulay sold 15,600 shares of CG Oncology stock in a transaction on Friday, April 17th. The shares were sold at an average price of $73.01, for a total transaction of $1,138,956.00. Following the completion of the transaction, the director directly owned 15,600 shares of the company’s stock, valued at $1,138,956. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 4.80% of the company’s stock.

Institutional Trading of CG Oncology

A number of large investors have recently made changes to their positions in CGON. Whittier Trust Co. of Nevada Inc. bought a new stake in shares of CG Oncology in the fourth quarter valued at about $27,000. NFSG Corp bought a new stake in shares of CG Oncology in the first quarter valued at about $34,000. Strengthening Families & Communities LLC bought a new stake in shares of CG Oncology in the third quarter valued at about $40,000. Comerica Bank raised its holdings in shares of CG Oncology by 100.4% in the fourth quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after acquiring an additional 515 shares in the last quarter. Finally, Fifth Third Bancorp bought a new stake in shares of CG Oncology in the first quarter valued at about $74,000. 26.56% of the stock is owned by hedge funds and other institutional investors.

More CG Oncology News

Here are the key news stories impacting CG Oncology this week:

• Positive Sentiment: HC Wainwright kept a Buy rating and $100 price target on CG Oncology, signaling continued confidence in the company’s long-term opportunity despite near-term losses. HC Wainwright analyst note
• Positive Sentiment: Other recent analyst actions also leaned constructive, including a new $81 target from RBC, a Buy rating from Truist, and a new $96 target from JPMorgan, which may be helping sentiment. RBC price target article
• Neutral Sentiment: HC Wainwright lowered earnings estimates for 2026–2029, reflecting expectations for larger losses in the near term, but it also raised its FY2030 EPS estimate to $6.77, implying a potentially meaningful long-term earnings ramp. HC Wainwright earnings estimate update
• Neutral Sentiment: CG Oncology’s recent presentation at the Bank of America Global Healthcare Conference and its presence at the AUA Annual Meeting keep investor attention on its clinical and commercial progress, but these items are not direct catalysts by themselves. Conference presentation transcript

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.